Prescription of opioids for breathlessness in end-stage COPD: a national population-based study

Zainab Ahmadi,1,2 Eva Bernelid,2 David C Currow,3 Magnus Ekström1–3 1Department of Clinical Sciences, Division of Respiratory Medicine and Allergology, Lund University Hospital, Lund, 2Department of Medicine, Blekinge Hospital, Karlskrona, Sweden; 3Discipline, Palliative and Supp...

Full description

Bibliographic Details
Main Authors: Ahmadi Z, Bernelid E, Currow DC, Ekström M
Format: Article
Language:English
Published: Dove Medical Press 2016-10-01
Series:International Journal of COPD
Subjects:
Online Access:https://www.dovepress.com/prescription-of-opioids-for-breathlessness-in-end-stage-copd-a-nationa-peer-reviewed-article-COPD
id doaj-cfb8eda6de0b4b9f91aa787dd101a1d7
record_format Article
spelling doaj-cfb8eda6de0b4b9f91aa787dd101a1d72020-11-24T21:06:52ZengDove Medical PressInternational Journal of COPD1178-20052016-10-01Volume 112651265729584Prescription of opioids for breathlessness in end-stage COPD: a national population-based studyAhmadi ZBernelid ECurrow DCEkström MZainab Ahmadi,1,2 Eva Bernelid,2 David C Currow,3 Magnus Ekström1–3 1Department of Clinical Sciences, Division of Respiratory Medicine and Allergology, Lund University Hospital, Lund, 2Department of Medicine, Blekinge Hospital, Karlskrona, Sweden; 3Discipline, Palliative and Supportive Services, Flinders University, Adelaide, SA, Australia Background: Low-dose opioids can relieve breathlessness but may be underused in late-stage COPD due to fear of complications, contributing to poor symptom control.Objectives: We aimed to study the period prevalence and indications of opioids actually prescribed in people with end-stage COPD.Methods: The study was a longitudinal, population-based study of patients starting long-term oxygen therapy (LTOT) for COPD between October 1, 2005 and June 30, 2009 in Sweden. A random sample (n=2,000) of their dispensed opioid prescriptions was obtained from the national Prescribed Drugs Register from 91 days before starting LTOT until the first of LTOT withdrawal, death, or study end (December 31, 2009). We analyzed medication type, dispensed quantity, date of dispensing, and indications categorized as pain, breathlessness, other, or unknown.Results: In total, 2,249 COPD patients (59% women) were included. During a median follow-up of 1.1 (interquartile range 0.6–2.0) years, 1,034 patients (46%) were dispensed ≥1 opioid prescription (N=13,722 prescriptions). The most frequently prescribed opioids were tramadol (23%), oxycodone (23%), morphine (16%), and codeine (16%). Average dispensed quantity was 9.3 (interquartile range 3.7–16.7) defined daily doses per prescription. In the random sample, the most commonly stated indication was pain (97%), with only 2% for breathlessness and 1% for other reasons.Conclusion: Despite evidence that supported the use of opioids for the relief of breathlessness predating this study, opioids are rarely prescribed to relieve breathlessness in oxygen-dependent COPD, potentially contributing to less-than-optimal symptom control. This study creates a baseline against which to compare future changes in morphine prescribing in this setting. Keywords: COPD, symptoms, breathlessness, opioids, prescriptions, LTOThttps://www.dovepress.com/prescription-of-opioids-for-breathlessness-in-end-stage-copd-a-nationa-peer-reviewed-article-COPDCOPDsymptomsbreathlessnessopioidsprescriptions
collection DOAJ
language English
format Article
sources DOAJ
author Ahmadi Z
Bernelid E
Currow DC
Ekström M
spellingShingle Ahmadi Z
Bernelid E
Currow DC
Ekström M
Prescription of opioids for breathlessness in end-stage COPD: a national population-based study
International Journal of COPD
COPD
symptoms
breathlessness
opioids
prescriptions
author_facet Ahmadi Z
Bernelid E
Currow DC
Ekström M
author_sort Ahmadi Z
title Prescription of opioids for breathlessness in end-stage COPD: a national population-based study
title_short Prescription of opioids for breathlessness in end-stage COPD: a national population-based study
title_full Prescription of opioids for breathlessness in end-stage COPD: a national population-based study
title_fullStr Prescription of opioids for breathlessness in end-stage COPD: a national population-based study
title_full_unstemmed Prescription of opioids for breathlessness in end-stage COPD: a national population-based study
title_sort prescription of opioids for breathlessness in end-stage copd: a national population-based study
publisher Dove Medical Press
series International Journal of COPD
issn 1178-2005
publishDate 2016-10-01
description Zainab Ahmadi,1,2 Eva Bernelid,2 David C Currow,3 Magnus Ekström1–3 1Department of Clinical Sciences, Division of Respiratory Medicine and Allergology, Lund University Hospital, Lund, 2Department of Medicine, Blekinge Hospital, Karlskrona, Sweden; 3Discipline, Palliative and Supportive Services, Flinders University, Adelaide, SA, Australia Background: Low-dose opioids can relieve breathlessness but may be underused in late-stage COPD due to fear of complications, contributing to poor symptom control.Objectives: We aimed to study the period prevalence and indications of opioids actually prescribed in people with end-stage COPD.Methods: The study was a longitudinal, population-based study of patients starting long-term oxygen therapy (LTOT) for COPD between October 1, 2005 and June 30, 2009 in Sweden. A random sample (n=2,000) of their dispensed opioid prescriptions was obtained from the national Prescribed Drugs Register from 91 days before starting LTOT until the first of LTOT withdrawal, death, or study end (December 31, 2009). We analyzed medication type, dispensed quantity, date of dispensing, and indications categorized as pain, breathlessness, other, or unknown.Results: In total, 2,249 COPD patients (59% women) were included. During a median follow-up of 1.1 (interquartile range 0.6–2.0) years, 1,034 patients (46%) were dispensed ≥1 opioid prescription (N=13,722 prescriptions). The most frequently prescribed opioids were tramadol (23%), oxycodone (23%), morphine (16%), and codeine (16%). Average dispensed quantity was 9.3 (interquartile range 3.7–16.7) defined daily doses per prescription. In the random sample, the most commonly stated indication was pain (97%), with only 2% for breathlessness and 1% for other reasons.Conclusion: Despite evidence that supported the use of opioids for the relief of breathlessness predating this study, opioids are rarely prescribed to relieve breathlessness in oxygen-dependent COPD, potentially contributing to less-than-optimal symptom control. This study creates a baseline against which to compare future changes in morphine prescribing in this setting. Keywords: COPD, symptoms, breathlessness, opioids, prescriptions, LTOT
topic COPD
symptoms
breathlessness
opioids
prescriptions
url https://www.dovepress.com/prescription-of-opioids-for-breathlessness-in-end-stage-copd-a-nationa-peer-reviewed-article-COPD
work_keys_str_mv AT ahmadiz prescriptionofopioidsforbreathlessnessinendstagecopdanationalpopulationbasedstudy
AT bernelide prescriptionofopioidsforbreathlessnessinendstagecopdanationalpopulationbasedstudy
AT currowdc prescriptionofopioidsforbreathlessnessinendstagecopdanationalpopulationbasedstudy
AT ekstromm prescriptionofopioidsforbreathlessnessinendstagecopdanationalpopulationbasedstudy
_version_ 1716764481752662016